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Abstract
Background: The purpose of this study was investigate the dose proportionality of a novel, once-
daily, controlled-release formulation of hydromorphone that utilizes the OROS® Push-Pull™
osmotic pump technology.
Methods: In an open-label, four-way, crossover study, 32 healthy volunteers were randomized to
receive a single dose of OROS® hydromorphone 8, 16, 32, and 64 mg, with a 7-day washout period
between treatments. Opioid antagonism was provided by three or four doses of naltrexone 50 mg,
given at 12-hour intervals pre- and post-OROS® hydromorphone dosing. Plasma samples for
pharmacokinetic analysis were collected pre-dose and at regular intervals up to 48 hours post-dose
(72 hours for the 64-mg dose), and were assayed for hydromorphone concentration to determine
peak plasma concentration (Cmax), time at which peak plasma concentration was observed (Tmax),
terminal half-life (t1/2), and area under the concentration-time curve for zero to time t (AUC0-t) and
zero to infinity (AUC0–∞). An analysis of variance (ANOVA) model on untransformed and dose-
normalized data for AUC0-t, AUC0–∞, and Cmax  was used to establish dose linearity and
proportionality.
Results: The study was completed by 31 of 32 subjects. Median Tmax (12.0–16.0 hours) and mean
t1/2 (10.6–11.0 hours) were found to be independent of dose. Regression analyses of Cmax, AUC0–
48, and AUC0–∞ by dose indicated that the relationship was linear (slope, P ≤ 0.05) and that the
intercept did not differ significantly from zero (P > 0.05). Similar analyses with dose-normalized
parameters also indicated that the slope did not differ significantly from zero (P > 0.05).
Conclusion: The pharmacokinetics of OROS® hydromorphone are linear and dose proportional
for the 8, 16, 32, and 64 mg doses.
Trial Registration: Clinical Trials.gov NCT00398957
Background
Hydromorphone hydrochloride (HCl), which is available
in immediate- and extended-release formulations, is a
semi-synthetic opioid agonist that has been used widely
for many years in the treatment of acute and chronic pain.
A number of studies have demonstrated the efficacy and
tolerability of hydromorphone in comparison with mor-
phine and other opioid analgesic agents [1]. When formu-
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lated as an immediate-release preparation,
hydromorphone has an elimination half-life of approxi-
mately 2 to 3 hours [2-4]. As a consequence, doses must
be administered every 4 to 6 hours to ensure continuous
analgesia for the patient [5].
To improve pain relief and provide convenient dosing for
patients with severe chronic cancer and non-cancer pain,
a novel 24-hour controlled-release formulation of hydro-
morphone is currently being investigated. This formula-
tion uses the patented OROS® Push-Pull™ osmotic pump
delivery system developed by ALZA Corporation (Palo
Alto, CA) [6-8], and a consistent release of hydromor-
phone over 24 hours has been demonstrated in healthy
volunteers [9]. Moreover, steady-state plasma concentra-
tions for OROS®  hydromorphone (Jurnista™, Janssen
Pharmaceutica, N.V., Beerse, Belgium) are achieved after
48 hours (i.e., after two doses or by the third dose) and are
maintained throughout the 24-hour dosing interval [10].
An initial study also has shown that the pharmacokinetics
of hydromorphone are not substantially affected when
OROS®  hydromorphone is taken immediately after a
high-fat meal [11].
Co-administration of OROS® hydromorphone with nal-
trexone, an opioid antagonist, under fasting conditions
resulted in a 39% increase in Cmax, but there was no signif-
icant change in Tmax, AUC0-t, or AUC0–∞ [11]. These results
indicate that blockade of opioid effects by naltrexone is
useful in comparative bioavailability studies of high-dose
opioids in healthy volunteers, with the assumption that
all treatments are affected similarly. The objective of the
present study was to evaluate the dose proportionality
and linearity of OROS® hydromorphone at daily doses of
8, 16, 32, and 64 mg.
Methods
Subjects
Study volunteers were non-smoking, healthy male and
female adults between 19 and 50 years of age. Their body
weight was required to be between 61 and 100 kg and
within ± 10% of the recommended weight range for
height and body frame (1984 Metropolitan Height and
Weight Tables). Results of the baseline screen were
required to be negative for drugs of abuse (cannabinoids,
opiates, cocaine, ethanol, and barbiturates). Subjects were
required to have no clinically significant deviations from
normal in laboratory results. All participants provided
written informed consent. The study was approved by the
Institutional Review Board and was carried out according
to the Declaration of Helsinki and subsequent revisions.
Subjects who were intolerant of, or hypersensitive to, opi-
oid agonists or antagonists were excluded, as were those
with opioid dependency. Other exclusion criteria
included gastrointestinal disorders; compromised cardiac,
respiratory, renal, or hepatic function; psychiatric abnor-
malities; and significant hematologic, metabolic, or cen-
tral nervous system disorders. Study participation did not
permit any subject to take any long-term medication,
enzyme-altering agents, recreational drugs, or an investi-
gational agent within 30 days of beginning the study.
Study design and interventions
This was an open-label, randomized, four-way crossover
study designed to examine the pharmacokinetic profile of
once-daily OROS® hydromorphone for dose proportion-
ality after administration of a single oral dose of 8, 16, 32,
and 64 mg.
Based on the assumption that the within-subject variabil-
ity is less than 20% (value guided by variability in expo-
sure following immediate-release hydromorphone) and
that there is a 5% difference between treatments, a sample
size of 30 subjects was estimated to provide 80% power to
demonstrate equivalence at the 0.05 level of significance.
Subjects received each of the four treatments (OROS®
hydromorphone 8, 16, 32, and 64 mg, given after a 10-
hour overnight fast), with a 7-day washout period
between treatments. The order in which treatments were
received was determined according to the predetermined
randomization schedule. Naltrexone 50 mg was adminis-
tered 12 hours before, with, and 12 hours after OROS®
hydromorphone in all groups, with an additional 50-mg
dose of naltrexone administered 24 hours after the 64-mg
dose of OROS® hydromorphone. Naltrexone was admin-
istered to minimize adverse events following the higher
doses of OROS® hydromorphone in these opioid-naïve
subjects, and was given concomitantly with each dose
level of OROS® hydromorphone to facilitate dose-propor-
tionality comparisons.
Plasma sampling
Plasma samples for pharmacokinetic analysis were col-
lected pre-dose (time 0) and at 2, 4, 6, 8, 10, 12, 16, 20,
24, 30, 36, 42, and 48 hours post-dose. Additional sam-
ples were taken at 56, 64 and 72 hours after the 64-mg
dose. Plasma hydromorphone concentrations were meas-
ured using a validated LC/MS/MS method (CEDRA Cor-
poration, Austin, TX) covering a range of 0.05 to 10 ng/
mL. Calibration standards prepared for each of the sample
sets were used to calculate the inter-day precision of the
assay. The coefficients of variation for the standards
ranged from 1.7% to 9.9%. The absolute deviations
ranged from 0.05% to 2.6%.
Based on the measured hydromorphone concentration,
the following parameters were calculated: peak plasma
concentration (Cmax), time at which peak plasma concen-BMC Clinical Pharmacology 2007, 7:3 http://www.biomedcentral.com/1472-6904/7/3
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tration was observed (Tmax), terminal half-life (t1/2), and
the area under the concentration-time curve from time 0
to time t (AUC0-t) and from time zero to infinity (AUC0–
∞). The non-compartmental pharmacokinetic parameters
described above were estimated using macros built in
Excel (Microsoft, Redmond, WA).
Statistical analysis
Untransformed and log-transformed (ln) data for Cmax,
AUC0-t and AUC0–∞ were analyzed using an appropriate
analysis of variance (ANOVA) regression model to estab-
lish dose linearity and dose proportionality. All tests were
two-sided at the 0.05 level of significance. Tmax was ana-
lyzed non-parametrically, without dose-normalization,
using the Wilcoxon matched-pairs test for each pairwise
comparison; the 95% confidence interval (CI) for the dif-
ference in treatment medians was constructed. Data for t1/
2 were summarized using descriptive statistics. The appar-
ent elimination-rate constant (K) for each subject was esti-
mated by linear regression of the log-transformed
concentration during the terminal log-linear decline
phase of the curve. Terminal half-life was estimated as
0.693/K.
Results
Subjects
Thirty-two healthy volunteers were enrolled in the study,
8 in each of four treatments, with at least 24 subjects
expected to complete the study. They were primarily male
(63%) and Caucasian (81%), with a mean age of 33 years
(Table 1). The study was completed by 31 subjects; one
subject discontinued for personal reasons, after complet-
ing the first phase of treatment (64-mg dose).
Pharmacokinetics
The plasma concentration-time profiles of the four
OROS® hydromorphone doses tested are shown in Figure
1. Following a single oral dose of OROS® hydromor-
phone, plasma mean concentrations gradually increase
over 6 to 8 hours, and thereafter are sustained at or near
maximum levels up to approximately 30 hours post-dose.
The means of untransformed pharmacokinetic parame-
ters and the medians of Tmax are shown in Table 2. Maxi-
mum plasma hydromorphone concentrations were
achieved approximately 12 to 16 hours after administra-
tion, with no significant dose effect observed. Mean values
for t1/2  were similar for the various doses (10.6–11.0
hours). Analysis of Cmax, AUC0-t, and AUC0–∞ by dose
indicated that the relationship was linear (P ≤ 0.05) and
that the intercept did not differ significantly from zero (P
> 0.05; Figure 2).
Mean dose-normalized pharmacokinetic parameters for
OROS® hydromorphone after administration of 8, 16, 32,
and 64 mg doses are shown in Table 3. Cmax and AUC
increased linearly and in a manner proportional to the
dose of OROS® hydromorphone. The slopes of dose-nor-
malized Cmax and AUC vs. dose did not differ signifi-
cantly from zero (P > 0.05; Figure 3). Inter-subject
variability in pharmacokinetic parameters was similar
across the doses except for high variability of Cmax fol-
lowing the 8-mg dose. This was mainly due to one subject
with a high concentration (>5 times the mean). When this
subject was excluded, Cmax variability for the 8-mg dose
was similar to the other doses. No significant gender-by-
treatment interactions were observed (ANOVA model;
data not shown).
Safety
At least one adverse event was experienced by 21 of the 32
subjects (66%). All events were of mild or moderate inten-
sity, and none were considered serious. Headache, asthe-
nia, and nausea were the most common adverse events,
occurring in 31%, 28%, and 28% of patients, respectively,
during one or more of the treatment periods. The adverse
events for each dose group are shown in Table 4. No treat-
ment-related trends were noted with regard to vital signs,
electrocardiogram results, or clinical laboratory data.
Discussion
The results of this study indicate that plasma hydromor-
phone concentrations and overall exposure to hydromor-
phone are proportional to the administered dose (over
the 8- to 64-mg dose range) with OROS® hydromorphone.
The time to achieve maximum plasma concentration was
independent of dose. Near-maximum plasma concentra-
tions were reached approximately 6 hours after dosing,
and plasma concentrations were maintained at or near
maximum levels throughout a 30-hour period, consistent
Table 1: Baseline characteristics
Characteristic All Participants (n = 32)
Sex, n (%)
Male 20 (62.5)
Female 12 (37.5)
Race, n (%)
Caucasian 26 (81.3)
Asian 3 (9.4)
Black 1 (3.1)
Hispanic 1 (3.1)
American Indian 1 (3.1)
Age (years)
Mean 33
Range 20–50
Height (cm)
Mean 175
Range 163–191
Weight (kg)
Mean 76.4
Range 61.4–96.4BMC Clinical Pharmacology 2007, 7:3 http://www.biomedcentral.com/1472-6904/7/3
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with once-daily dosing. Beginning 24 to 30 hours post-
dose, plasma hydromorphone concentrations declined
slowly, with an apparent terminal half-life of approxi-
mately 10 hours. This is longer than the half-life of imme-
diate-release hydromorphone (2–3 hours), which has
been determined from studies with intravenous formula-
tions [2-4]. The present study included plasma sampling
for up to 72 hours post-dose, and it was designed to char-
acterize both the controlled-release and the post-absorp-
tive elimination phases of the drug. The apparent terminal
half-life observed in this study is similar to that seen in a
study designed to assess the effects of food intake on the
pharmacokinetics of OROS® hydromorphone [11]. The
observed plasma profile with concentration maintained
over 24 hours supports the proposed once-daily adminis-
tration of OROS® hydromorphone.
An exploratory analysis suggested no influence of gender
on the pharmacokinetics of OROS® hydromorphone for
the dose range studied. Although limited, these data do
suggest that there are no clinically relevant differences
Mean plasma hydromorphone concentrations over time after administration of single-dose OROS® hydromorphone Figure 1
Mean plasma hydromorphone concentrations over time after administration of single-dose OROS® hydromorphone.
Table 2: Untransformed pharmacokinetic parameters after administration of OROS® hydromorphone 8, 16, 32, and 64 mg (n = 31)
Parameter 8 mg 16 mg 32 mg 64 mg
Cmax (ng/mL)
Mean 0.929 1.69 3.25 6.61
SD 1.01 0.78 1.37 1.75
Tmax (hour)
Median 12.0 16.0 16.0 16.0
Range 4.0–30.0 6.0–30.0 4.0–24.0 6.0–30.0
AUC0–48 (ng·hr/mL)
Mean 18.1 36.5 72.2 156
SD 5.8 11.3 24.3 30.6
AUC0–∞ (ng·hr/mL)
Mean 19.5 40.8 80.3 178.7
SD 5.9 13.7 29.6 35.2
t1/2 (hour)
Mean 10.6 10.3 11.0 10.9
S D 4 . 32 . 43 . 23 . 8BMC Clinical Pharmacology 2007, 7:3 http://www.biomedcentral.com/1472-6904/7/3
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Analyses of dose linearity with OROS® hydromorphone: (A) Cmax/dose; (B) AUC0–48/dose Figure 2
Analyses of dose linearity with OROS® hydromorphone: (A) Cmax/dose; (B) AUC0–48/dose. Dashed lines represent 95% CI.BMC Clinical Pharmacology 2007, 7:3 http://www.biomedcentral.com/1472-6904/7/3
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Analyses of dose proportionality with OROS® hydromorphone: (A) Cmax/dose; (B) AUC0–48/dose Figure 3
Analyses of dose proportionality with OROS® hydromorphone: (A) Cmax/dose; (B) AUC0–48/dose. Dashed lines represent 95% 
CI.BMC Clinical Pharmacology 2007, 7:3 http://www.biomedcentral.com/1472-6904/7/3
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between males and females with respect to the pharma-
cokinetics of OROS® hydromorphone.
Safety results were consistent for all four OROS® hydro-
morphone doses, indicating no dose relationship with the
incidence of adverse events. Adverse events were consist-
ent with those expected for an opioid agonist and antago-
nist and primarily affected the digestive and central
nervous systems. No serious adverse events were reported
during the study.
Conclusion
Plasma concentrations of OROS® hydromorphone and its
pharmacokinetic parameters were found to be propor-
tional to the orally administered dose over the dose range
studied (8 mg to 64 mg). Plasma concentrations achieved
the maximal level by approximately 16 hours after single
administration, independently of dose, and remained
near that level for up to 30 hours. Adverse events were
consistent with those expected for an opioid agonist and
antagonist.
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